CD80 and cancer: While the PD-1-PD-L1/L2 and CTLA4-CD80/86 axes are regarded as key immune checkpoint components in various cancers, our findings revealed that they were lowly expressed and this might raise an uncertainty of their functions in treatment-naïve HCC patients.